RESUMEN
Vasoactive intestinal peptide (VIP) has been shown to regulate early postimplantation growth in rodents through central nervous system receptors. However, the source of VIP mediating these effects is unknown. Although VIP binding sites are present prenatally, VIP mRNA was not detected in the rat central nervous system before birth and was detected in the periphery only during the last third of pregnancy. In the present study, the embryonic day (E11) rat embryo/trophoblast was shown to have four times the VIP concentration of the E17 fetus and to have VIP receptors in the central nervous system. However, no VIP mRNA was detected in the E11 rat embryo or embryonic membranes by in situ hybridization or reverse transcriptase-PCR. RIA of rat maternal serum revealed a peak in VIP concentration at days E10-E12 of pregnancy, with VIP rising to levels 6-10-fold higher than during the final third of pregnancy. After intravenous administration of radiolabeled VIP to pregnant female mice, undegraded VIP was found in the E10 embryo. These results suggest that maternal tissues may provide neuroendocrine support for embryonic growth through a surge of VIP during early postimplantation development in the rodent.
Asunto(s)
Embrión de Mamíferos/química , Desarrollo Embrionario y Fetal/fisiología , Péptido Intestinal Vasoactivo/análisis , Animales , Secuencia de Bases , Encéfalo/embriología , Química Encefálica , Femenino , Hibridación in Situ , Intercambio Materno-Fetal , Ratones , Datos de Secuencia Molecular , Placenta/química , Reacción en Cadena de la Polimerasa/métodos , Embarazo , ARN Mensajero/análisis , ARN Mensajero/sangre , Ratas , Somatostatina/sangre , Médula Espinal/química , Médula Espinal/embriología , Trofoblastos/química , Péptido Intestinal Vasoactivo/sangre , Péptido Intestinal Vasoactivo/metabolismo , alfa-MSH/sangreRESUMEN
Previous work has shown that blockade of VIP function in the early postimplantation embryo results in growth retardation and microcephaly. In the present work, the neurobehavioral development of neonatal mice was examined following treatment of dams with a VIP antagonist during this period. Inhibition of VIP functions during early embryogenesis impaired the performance of 5 of 10 developmental behaviors. These behaviors included developmental milestones (first appearance of ear twitch and eye opening) and complex motor behaviors (negative geotaxis, surface righting, and air righting). The retardation of neurobehavioral development produced by inhibition of VIP action indicates that this peptide is important to the progression of embryonic development.